Gain Therapeutics, Inc.

NASDAQ:GANX

Biotechnology

Healthcare
$1.18 +3.09%

+$0.06 today

Market cap
$50.33M
Beta
0.16
P/E (TTM)
-3.6
EPS (TTM)
-$0.50
52W Low $1.41High $4.34

Volume 4.26M

Average 0.64M

Balance Sheet

Inspect the capital base behind the business.

Assets

$22.82M

FY 2025 · Annual

+88.2% YoY

Liabilities

$4.25M

FY 2025 · Annual

-11.1% YoY

Equity

$18.56M

FY 2025 · Annual

+152.9% YoY

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents36.88M7.31M11.79M10.39M20.84M
Short-term Investments012.83M5M00
Net Receivables195.45K103.88K242.58K765.76K802.69K
Inventory00000
Other Current Assets0640.31K0369.89K275.43K
Total Current Assets37.72M21.09M17.78M11.6M22.24M
Property, Plant & Equipment (Net)1.01M804.31K585.18K323.33K409.01K
Goodwill00000
Intangible Assets202.61K213.97K193.38K134.27K102.84K
Long-term Investments31.28K1.94M34.02K31.7K36.3K
Tax Assets(31.28K)0000
Other Non-current Assets53.39K48.32K17.89K32.11K33.7K
Total Non-current Assets1.26M3.01M830.46K521.41K581.84K
Total Assets38.99M24.1M18.61M12.12M22.82M
Account Payables560.48K1.63M1.32M946.26K825.03K
Short-term Debt103.83K108.14K118.8K110.18K100.87K
Tax Payables380107.31K48.97K00
Deferred Revenue266.5K55.18K1.12M252.21K0
Other Current Liabilities380364.11K1.38M18.49K167.89K
Total Current Liabilities2.55M4.13M4.95M3.91M3.35M
Long-term Debt590.47K495.26K449.05K328.33K300.08K
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)0094.79K47.44K0
Other Non-current Liabilities329.46K157.58K307.45K443.62K390.51K
Total Non-current Liabilities1.61M1.09M1.08M872.99K901.83K
Total Liabilities4.17M5.22M6.03M4.78M4.25M
Common Stock1.19K1.19K1.62K2.71K4.21K
Retained Earnings(20.93M)(38.52M)(60.78M)(81.19M)(101.36M)
Accumulated OCI(90.65K)35.63K247.24K(247.55K)776.87K
Other Stockholders Equity00000
Minority Interest00000
Total Equity34.82M18.88M12.58M7.34M18.56M
Total Debt1.61M1.27M1.03M653.02K732.07K
Net Debt(35.27M)(6.04M)(10.77M)(9.73M)(20.11M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$16.5M
Receivables$994.6K
Other Current$687.9K
Total Current Assets$18.2M
PP&E (Net)$355.0K
Intangible Assets$90.0K
Long-term Investments$36.1K
Other Non-current$35.6K
Total Non-current Assets$516.7K
Total Assets$18.7M

Analysis

Selected assets total $18.7M for Latest. The largest visible component is Cash & Equivalents at $16.5M, about 88.3% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 17, 2026
8-KCurrent reportNov 10, 2026
10-QQuarterly reportNov 10, 2026
4Statement of changes in beneficial ownershipOct 30, 2026
3Initial statement of beneficial ownershipOct 30, 2026

How much cash does GANX have?

Gain Therapeutics, Inc. (GANX) reported $20.84M in cash and equivalents in fiscal 2025.

How much debt does GANX carry?

Gain Therapeutics, Inc. (GANX) reported $732,067.00 of total debt, with net debt of -$20.11M.